Companies / Israel
Lack Of Funds Holds Back Biotech
May 2007 | Industry NewsIsrael's biotech industry, although seemingly healthy, is suffering from a lack of scale claim industry observers in the country. Although there are over 160 separate companies in the country, only six have a listing on the Nasdaq Stock Exchange with a combined market capitalisation of US$1.4bn. By comparison, in the US city of San Diego alone, there are 100 biotech firms, of which 30 are public and have a combined cap of
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
